Advertisement

Topics

PHAROS GmbH Company Profile

07:31 EDT 23rd May 2018 | BioPortfolio

PHAROS GmbH is a Contract Research Organisation for Early Clinical Research and various related services. All of our services are custom designed, thus these pages are only a guide to the types of services we are able to offer.Our main services are:
Clinical Trial Services
Phase I Study Services
• Bioequivalence Study Services
• Clinical Trial Elements and Procedures
Quality Management Services
Monitoring, Audit and Quality Management Services

Location

Horvelsinger Weg 52-1
Ulm
89081
Germany

Contact

Phone: 49-731-96 46-0
Fax: 49-731-96 46-600
Email: info@pharos-gmbh.com


News Articles [139 Associated News Articles listed on BioPortfolio]

Systec GmbH Introduces its new Business Partner Evidencia GmbH

Research, pharmaceuticals, life sciences and food: many laboratories rely on steam sterilizers or equipment where processes are monitored using pressure and temperature control. Thanks to our collabor...

Pharos Capital’s Family Treatment Network Acquires Behavior Care Specialists

Autism Disorder Treatment Services Add to Firm’s Behavioral Health Portfolio Pharos Capital Group, LLC (“Pharos”), through its Family Treatment Network platform (...

Original-Research: Medigene AG (von EQUITS GmbH): Kaufen

Original-Research: Medigene AG - von EQUITS GmbH Einstufung von EQUITS GmbH zu Medigene AG Unternehmen: Medigene AG ISIN: DE000A1X3W00 Anlass der Studie: Übernahme-Angebot Empfehlung: Kaufen Kursz...

Pharos Capital Launches Verdi Oncology an Oncology Practice and Clinical Research Management Platform

Acquires Horizon Oncology in Indiana as Platform’s First Investment Pharos Capital Group, LLC (“Pharos”), a private equity firm based in Dallas and Nashville, announced ...

PH-FIX Indikatorstäbchen pH 4,5-10 100 St MACHEREY-NAGEL GMBH & CO. KG

EUR 10,24Angebotsende: Samstag Apr-7-2018 11:22:08 CESTSofort-Kaufen für nur: EUR 10,24Sofort-Kaufen | Zur Liste der beobachteten Artikel hinzufügen Biotech365 : PH-FIX Indikatorstäbchen pH 4,...

NexWafe GmbH schließt Finanzierung in Höhe von 8 Millionen Euro ab

NexWafe GmbH, ein Spin-off des Fraunhofer ISE, das eine bahnbrechende Technologie zur epitaktischen Herstellung von Siliziumwafern für Photovoltaik kommerzialisiert, gab heute den Abschluss einer F...

United Technologies Corporation: Aus Carrier und CIAT wird UTC Klimatechnik GmbH

Innerhalb der UTC Klimatechnik GmbH werden die beiden Marken als getrennte Geschäftsbereiche geführt. Die Vertriebsleitung für CIAT hat zum Jahresanfang Reinhard Kern übernommen. Der Kälteanlagen...

Gerresheimer-Aktie: Dividendenerhöhung auch für 2018? Kaufempfehlung

Frankfurt am Main - Gerresheimer-Aktienanalyse von der EQUI.TS GmbH: Thomas J. Schießle und Daniel Großjohann, Aktienanalysten der EQUI.TS GmbH, nehmen in einer aktuellen Aktienanalyse die Coverage....

PubMed Articles [14 Associated PubMed Articles listed on BioPortfolio]

Correction to: Lonoctocog Alfa: A Review in Haemophilia A.

The article Lonoctocog Alfa: A Review in Haemophilia A, written by Zaina T. Al-Salama and Lesley J. Scott, was originally published Online First without open access. After publication in volume 77...

Long-term Outcomes in Systemic Sclerosis Associated Pulmonary Arterial Hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS).

Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). The purpose of this study was to assess long-term outcomes in patients with SSc-PAH.

Ocular Impression-Taking-Which Material Is Best?

To assess the efficacy and effect on clinical signs of a polyvinylsiloxane (Tresident; Shütz Dental Group GmbH, Germany) compared with an irreversible hydrocolloid (Orthoprint; Zhermack SpA, Badia Po...

Subconjunctival minimally invasive glaucoma surgery : Methods and clinical results.

Minimally invasive glaucoma surgery (MIGS) has been developed for all drainage pathways in glaucoma treatment. Besides implants overriding the resistance in the trabecular meshwork (iStent®, iStent I...

Postoperative Corneal Asphericity in Low, Moderate, and High Myopic Eyes After Transepithelial PRK Using a New Pulse Allocation.

To evaluate the postoperative asphericity in low, moderate, and high myopic eyes after combined transepithelial photorefractive keratectomy and SmartSurfACE treatment (SCHWIND eye-tech-solutions GmbH,...

Clinical Trials [44 Associated Clinical Trials listed on BioPortfolio]

VISSIT Intracranial Stent Study for Ischemic Therapy

The main objective of this study is to prospectively evaluate the safety, probable benefit, and effectiveness of the PHAROS Vitesse Neurovascular Stent System in a multicenter, randomized ...

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied - Products, dosage, and route of administration: ...

XC8 in the Treatment of Patients With Bronchial Asthma

A multicenter, double-blind, randomized, parallel-group comparative Phase II clinical study to assess the efficacy and safety of different doses of XC8 vs Placebo in patients with partly c...

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

User Performance Evaluation of Contour® Plus One, Accu-Chek® Performa Connect, FreeStyle Optium Neo and OneTouch® Select Plus Blood Glucose Monitoring Systems Following ISO 15197:2013; EN ISO 15197:2015

The user performance evaluation shows whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system. In this study, user performance e...

Companies [534 Associated Companies listed on BioPortfolio]

PHAROS GmbH

PHAROS GmbH is a Contract Research Organisation for Early Clinical Research and various related services. All of our services are custom designed, thus these pages are only a guide to the types of ser...

Pharos Capital Group, LLC

Based in Dallas and Nashville, Pharos (www.pharosfunds.com) primarily invests $10 to $30 million in companies seeking later stage equity funding for internal growth, acquisitions,...

Pharos Innovations

Founded in 1995, Pharos Innovations assists healthcare providers and payers in achieving next generation clinical and financial performance improvement. An innovative, device-free platform, Tel-Assura...

Chemie-Kontor GmbH

Chemie-Kontor GmbH trades with chemical specialities for customers in Pharma-, Agro-, Cosmetics and Nutrition Industries and offers a broad range of services. Chemie-Kontor GmbH is agent for: Amberger...

OctreoPharm Sciences GmbH

OctreoPharm Sciences GmbH, located in Berlin (Germany) is a privately held clinical development company focusing on radiopharmaceuticals for the diagnosis and therapeutic control ...

More Information about "PHAROS GmbH" on BioPortfolio

We have published hundreds of PHAROS GmbH news stories on BioPortfolio along with dozens of PHAROS GmbH Clinical Trials and PubMed Articles about PHAROS GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of PHAROS GmbH Companies in our database. You can also find out about relevant PHAROS GmbH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Corporate Database Quicklinks



Searches Linking to this Company Record